Anika Therapeutics第二季度。每股收益$（0.13）击败$（0.17）估计，销售额2，822万美元，超过2，770万美元估计

Anika Therapeutics (NASDAQ: ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 176.47 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $28.22 million which beat the analyst consensus estimate of $27.70 million by 1.87 percent. This is a 32.69 percent decrease over sales of $41.92 million the same period last year.